Kato, Ryoji
Hayashi, Hidetoshi http://orcid.org/0000-0001-8787-5587
Chiba, Yasutaka
Miyawaki, Eriko
Shimizu, Junichi
Ozaki, Tomohiro
Fujimoto, Daichi
Toyozawa, Ryo
Nakamura, Atsushi
Kozuki, Toshiyuki
Tanaka, Kentaro
Teraoka, Shunsuke
Usui, Kazuhiro
Nishino, Kazumi
Hataji, Osamu
Ota, Keiichi
Ebi, Noriyuki
Saeki, Sho
Akazawa, Yuki
Okuno, Motoyasu
Yamamoto, Nobuyuki
Nakagawa, Kazuhiko
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study
https://doi.org/10.1136/jitc-2023-006994
Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
https://doi.org/10.1136/jitc-2022-005801
Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer (WJOG10217L)
https://doi.org/10.1136/jitc-2019-000350
Funding for this research was provided by:
West Japan Oncology Group